Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate

被引:0
|
作者
Tapia, Rodrigo [1 ]
Mena, Juan [1 ]
Garcia, Victoria [1 ]
Culhane, Marie [2 ]
Medina, Rafael A. [3 ,4 ,5 ]
Neira, Victor [1 ]
机构
[1] Univ Chile, Fac Ciencias Vet, Med Prevent Anim, Santiago, Chile
[2] Univ Minnesota, Coll Vet Med, Vet Populat Med, St Paul, MN USA
[3] Emory Univ, Sch Med, Dept Pathol & Expt Med, Atlanta, GA USA
[4] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY USA
[5] Pontificia Univ Catolica Chile, Escuela Med, Dept Enfermedades Infecciosas Inmunol Pediat, Santiago, Chile
关键词
influenza; swine; vaccine; cross-protection; guinea pig model; surrogate; NEURAMINIDASE; TRANSMISSION;
D O I
10.3389/fvets.2023.1245278
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Influenza A virus poses a significant threat to public health and the swine industry. Vaccination is the primary measure for controlling the disease, but the effectiveness of vaccines can vary depending on the antigenic match between vaccine strains and circulating strains. In Chile, H1N1pdm09 and other lineages H1N2 and H3N2 have been detected in pigs, which are genetically distinct from the strains included in commercial vaccines. This study aimed to evaluate the cross-protection by commercial vaccines against strains circulating in Chile using the guinea pig model. For this study, four circulating strains [A/swine/Chile/H1A-7/2014(H1N2), A/swine/Chile/H1B-2/2014(H1N2), A/swine/Chile/H1P-12/2015(H1N1), and A/swine/Chile/H3-2/2015(H3N2)] were selected. Guinea pigs were divided into vaccinated and control groups. The vaccinated animals received either a multivalent antigenically heterologous or monovalent homologous vaccine, while the control animals remained unvaccinated. Following vaccination, all animals were intranasally challenged, and nasal wash samples were collected at different time points post-infection. The results showed that the homologous monovalent vaccine-induced hemagglutinin-specific antibodies against the Chilean pandemic H1N1pdm09 strain. However, the commercial heterologous multivalent vaccine failed to induce hemagglutinin-specific antibody titers against the H1N2 and H3N2 challenge strains. Furthermore, the homologous monovalent vaccine significantly reduced the duration of viral shedding and viral titers specifically against the Chilean pandemic H1N1pdm09 strain and heterologous multivalent vaccine only partial. These findings highlight the importance of regularly updating vaccine strains to match the circulating field strains for effective control of swine influenza. Further research is needed to develop vaccines that confer broader protection against diverse strains of swine influenza A virus.
引用
收藏
页数:7
相关论文
共 44 条
  • [21] Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
    Wenling Wang
    Baoying Huang
    Xiuping Wang
    Wenjie Tan
    Li Ruan
    Virologica Sinica, 2019, (05) : 583 - 591
  • [22] Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles
    Kim, Yeu-Chun
    Yoo, Dae-Goon
    Compans, Richard W.
    Kang, Sang-Moo
    Prausnitz, Mark R.
    JOURNAL OF CONTROLLED RELEASE, 2013, 172 (02) : 579 - 588
  • [23] Prior infection of pigs with a recent human H3N2 influenza virus confers minimal cross-protection against a European swine H3N2 virus
    Qiu, Yu
    van der Meulen, Karen
    Van Reeth, Kristien
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2013, 7 (06) : 1260 - 1268
  • [24] Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection
    Handabile, Chimuka
    Sekiya, Toshiki
    Nomura, Naoki
    Ohno, Marumi
    Kawakita, Tomomi
    Shingai, Masashi
    Kida, Hiroshi
    VACCINES, 2022, 10 (05)
  • [25] Likelihood of prior exposure to circulating influenza viruses resulting in cross-protection by CD8+T cells against emergent H3N2v swine viruses infecting humans
    Komadina, Naomi
    Sullivan, Sheena G.
    Leder, Karin
    McVernon, Jodie
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (02) : 567 - 574
  • [26] Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model
    Zhou, Yongchao
    Chen, Dong
    Yang, Lan
    Zou, Weiwei
    Duan, Zhiliang
    Zhang, Yanjun
    Wen, Jinsheng
    VIRUS RESEARCH, 2020, 278
  • [27] Immunity to Pre-1950 H1N1 Influenza Viruses Confers Cross-Protection against the Pandemic Swine-Origin 2009 A (H1N1) Influenza Virus
    Skountzou, Ioanna
    Koutsonanos, Dimitrios G.
    Kim, Jin Hyang
    Powers, Ryan
    Satyabhama, Lakshmipriyadarshini
    Masseoud, Feda
    Weldon, William C.
    Martin, Maria del Pilar
    Mittler, Robert S.
    Compans, Richard
    Jacob, Joshy
    JOURNAL OF IMMUNOLOGY, 2010, 185 (03) : 1642 - 1649
  • [28] Soluble Recombinant Hemagglutinin Protein of H1N1pdm09 Influenza Virus Elicits Cross-Protection Against a Lethal H5N1 Challenge in Mice
    Yamada, Shinya
    Yasuhara, Atsuhiro
    Kawaoka, Yoshihiro
    FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [29] Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model
    Shen, Xuefei
    Soderholm, Jonas
    Lin, Feng
    Kobinger, Gary
    Bello, Alexander
    Gregg, Derek A.
    Broderick, Kate E.
    Sardesai, Niranjan Y.
    VACCINE, 2012, 30 (48) : 6946 - 6954
  • [30] Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine
    Carter, Donald M.
    Bloom, Chalise E.
    Kirchenbaum, Greg A.
    Tsvetnitsky, Vadim
    Isakova-Sivak, Irina
    Rudenko, Larisa
    Ross, Ted M.
    VACCINE, 2015, 33 (01) : 108 - 116